Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JGA Issues Written Reprimand to Sawai over GMP Issues
The Japan Generic Medicines Association (JGA) has issued a written reprimand to Sawai Pharmaceutical after the generic giant was slapped with business improvement orders over its fraudulent testing of the gastritis and gastric ulcer drug Teprenone Capsules. A reprimand is…
To read the full story
Related Article
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
- (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
- Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
- Sawai’s Misconduct Severely Undermines Credibility of Generics: Health Minister
October 25, 2023
- Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
ORGANIZATION
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
- Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…